Anaesthetic Ear Drop

Quick links

Choose a section

Quick links to important sections

Advertisements

Anaesthetic Ear Drop

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Anaesthetic Ear Drop

Quick Facts

Property Description
Active Ingredients Phenazone and Tetracaine
Form Otic Solution (Ear Drops)
Pharmacological Class Analgesic and Local Anaesthetic Combination
General Purpose Symptomatic management of ear pain
Origin Synthetic Compounds

Identity and Pharmacological Classification

Anaesthetic Ear Drop is a combination medicinal product, specifically formulated as an otic solution intended for topical auricular use. Pharmacologically, it is classified as a dual preparation featuring an analgesic and a local anaesthetic. This specific combination of Phenazone and Tetracaine is clinically recognized for providing combined pain relief and surface numbness. Unlike single-agent ear solutions, this preparation is designed to address both the pain sensation and the localized discomfort that often accompanies it, establishing its role solely in symptom palliation.

Composition and Delivery Form

The product's efficacy hinges on its two synthetic active ingredients: Phenazone, which provides the analgesic and mild anti-inflammatory component, and Tetracaine, an ester-type local anaesthetic known for rapidly blocking nerve impulse conduction. Combining these agents achieves a localized synergy, with the anaesthetic providing immediate effect while the analgesic sustains comfort. Delivered as Ear Drops in a viscous base like glycerin, the solution's physical form ensures maximum contact with the external auditory canal and tympanic membrane, enabling the rapid and concentrated delivery essential for treating acute localized pain.

General Purpose and Symptomatic Benefit

The general purpose of this combination ear drop is the short-term, symptomatic management of acute, localized earache and sensitivity. A typical use scenario involves mitigating the sharp, sudden pain associated with ear inflammation. By applying the anaesthetic and analgesic agents directly to the site of irritation, the product offers the practical benefit of prompt, focused relief from discomfort. It is a crucial differentiating factor that this product is strictly for pain management and does not possess antibiotic properties, meaning its function is limited to addressing the symptom of pain itself.

Regulatory References

  1. MedlinePlus: Earache
Advertisements

What side effects are possible with Anaesthetic Ear Drop?

Possible Side Effects and Safety Information

The safety profile for this combination otic solution (Phenazone and Tetracaine) is structured around localized effects at the site of application and critical limitations related to ear anatomy, based on regulatory labeling.


Adverse Reaction Scope

Category Description
Key adverse reaction categories Primarily local application site reactions and the potential for systemic allergic reactions.
Frequency classification Frequency is generally not known for many reported effects, as specific numerical data are often absent in core labeling for topical otic preparations.
System-organ classes involved Ear and Labyrinth Disorders, Skin and Subcutaneous Tissue Disorders, and Immune System Disorders.
Serious adverse reactions Ototoxicity (inner ear damage, hearing loss) if the product enters the middle ear, and rare systemic hypersensitivity reactions (e.g., anaphylaxis).

Regulatory Safety Constraints

Constraint Area Specific Limitation
Membrane Integrity The product is contraindicated if the tympanic membrane (eardrum) is perforated due to the critical risk of inner ear damage from the active ingredients.
Administration The product is strictly for external otic use only and is generally limited to short-term symptomatic management as defined by regulatory documents.
Population Safety and efficacy are not established in certain younger pediatric patients (e.g., infants under 6 months).

The regulatory profile emphasizes that while common adverse effects are transient local reactions like stinging or burning upon application, the overall risk assessment is defined by the absolute contraindication regarding a non-intact eardrum. This constraint is critical to prevent the escalation of risk from minor local effects to severe, documented inner ear damage.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Anaesthetic Ear Drop overdose focuses on the risk of systemic toxicity resulting from excessive exposure or accidental ingestion. Systemic toxicity, primarily due to the local anaesthetic component, is documented to affect the neurologic and cardiovascular systems. Manifestations of overdose include severe neurologic effects such as seizure, coma, confusion, and tinnitus. Serious cardiovascular effects like uneven heartbeats and chest pain are also listed.

Life-threatening outcomes, including respiratory failure and stopping of the heart, are recognized as potential consequences. Immediate medical intervention is mandated for all cases of accidental ingestion. The regulatory labeling explicitly instructs users to seek emergency medical attention or call the Poison Help line if the medication is swallowed. Further, emergency services must be contacted immediately if the affected person has collapsed or is not breathing.

Supportive and symptomatic care is the prescribed management, as no specific antidote is known. Certain populations face an increased risk of severe complications, notably infants under the age of twelve months and patients with glucose-6-phosphate dehydrogenase deficiency. Close monitoring for signs of metabolic complications is required for these susceptible groups.

Advertisements

Therapeutic Uses of Anaesthetic Ear Drop

What Anaesthetic Ear Drop treats: Main Uses and Benefits

Anaesthetic ear drops provide symptomatic support by directly targeting symptoms related to physical discomfort in the ear. This category of medication is commonly used for the supportive relief of pain and discomfort in conditions like acute otitis media, barotrauma (pain from pressure changes), and external ear irritation.

Focus on Symptom Relief

This medication is relevant for easing symptoms related to certain distressing symptoms for acute pain, throbbing, or sharpness arising specifically in the ear. It helps manage the pronounced distress associated with acute otalgia, and may contribute to easing the localized distress that may help patients cope more steadily with symptom fluctuations related to ear discomfort. It is relevant in contexts marked by increased discomfort or tension arising from environmental factors, such as post-swimming irritation or pressure discomfort after air travel.

“It is applied in scenarios where additional management of discomfort is required, offering supportive relief when symptoms interfere with routine activities.”

The medication may assist with maintaining functional stability by easing the localized symptomatic discomfort, which may interfere with daily functioning, and supports general well-being during symptomatic phases.

Quick Fact: Relief for Acute Localized Ear Pain

Regulatory References

  1. Antipyrine and Benzocaine Otic Solution Indications
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Anaesthetic Ear Drop?

Eligibility for using anaesthetic ear drops is strictly governed by official regulatory guidelines, primarily focusing on the integrity of the eardrum and patient history. These guidelines establish clear criteria for use and formal prohibitions.

Official Eligibility Profile

Classification Status and Condition
Allowed Patients with an intact tympanic membrane and no known history of allergy to the ingredients.
Contraindicated Patients with a perforated eardrum or a tympanostomy tube (ear tube) inserted.
Contraindicated Patients with known hypersensitivity or allergy to any active substance (e.g., benzocaine, lidocaine) or excipient.
Not Established Pediatric use for certain formulations is not established or recommended in children under two years of age.

Summary of Eligibility Constraints

Regulatory documents universally prohibit the use of these drops if the tympanic membrane is perforated or if tympanostomy tubes are present, as this constitutes an absolute contraindication. Use is further restricted by a mandatory exclusion for patients with a documented allergy to any component. For specific drug formulations, a minimum age of two years often establishes the lower limit for patient eligibility.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Anaesthetic Ear Drops focuses on limiting systemic exposure and avoiding additive toxic effects, particularly when the tympanic membrane is compromised. Due to the generally low systemic absorption of otic preparations, most clinically significant interaction data are derived from related systemic local anesthetics, which apply if absorption is increased.


Documented Interaction Entities

Interaction Type Interacting Substances/Conditions
Pharmacodynamic Interactions Other Local Anaesthetics or Class I Antiarrhythmics (additive toxicity); CNS Depressants (additive sedation effects).
Pharmacokinetic Interactions Inhibitors of Hepatic Metabolism (e.g., Cimetidine, Propranolol, Fluvoxamine), which can increase plasma levels of the anaesthetic component.
Contraindication/Constraint Perforation of the Tympanic Membrane (increases systemic absorption, enhancing the risk of interactions and toxicity).

Regulatory Summary

The official labeling requires caution against co-administration with other products that share similar effects on the nervous system or cardiac function, as this leads to an enhanced risk of adverse effects. Drugs known to reduce the clearance of related local anesthetics, such as certain H2 antagonists and beta-blockers, may cause elevated systemic concentrations of the ear drop's active ingredients. Patients with hepatic impairment are noted to be at an increased risk for such interactions due to potentially reduced metabolism.

Advertisements

Mechanism of Action

The mechanism is defined by a dual-action pharmacodynamic system that modulates nociceptive signaling at both the nerve transmission level and the biochemical mediator level. This pharmacodynamic coordination involves Tetracaine's rapid onset of peripheral sensory interruption and Phenazone's sustained pathway modulation.

Nerve Impulse Blockade via Nav Channel Inhibition

This domain focuses on the Tetracaine mechanism, which is characterized by rapid kinetics and targets the Voltage-Gated Sodium Channels (Nav) on peripheral sensory nerves. By acting as a channel blocker, Tetracaine prevents the necessary influx of sodium ions, which stops the electrical current (action potential) from traveling along the nerve fibre. This molecular blockade results in the inhibition of action potential propagation along the sensory nerve fibre, defining the mechanism of localized peripheral sensory loss.

Modulation of Inflammatory Mediator Synthesis

This domain covers the Phenazone mechanism, which is associated with sustained pathway modulation and addresses the Arachidonic Acid Cascade. Phenazone functions as a non-selective inhibitor of the Cyclooxygenase (COX) enzyme, thereby reducing the local production of Prostaglandins (PGs). This reduction in PGs decreases the sensitization of local pain receptors, resulting in a modulation of nociceptor activity.

Pharmacodynamic Synergy and Dual Interception

The combination mechanism utilizes pharmacodynamic synergy: the nerve impulse blockade mechanism involves rapid interruption of sensory impulse transmission, while the inflammatory mediator modulation mechanism supports sustained pathway modulation. This coordinated action targets both the electrical and biochemical elements of the localized physiological response.

Advertisements

Dosage and Administration Information

Instruction Map: How to use Anaesthetic Ear Drop — Administration Guidelines

Instruction Entity Standard Protocol
Route of administration Strictly Auricular (Otic) Route for topical use in the external auditory canal only.
Dosing schedule (Standard guidelines) Instillation of 4 drops per dose, or enough solution to fill the entire ear canal (2 to 4 drops), is the standard regimen.
Timing in relation to meals (if applicable) Not applicable. This is a local, topical solution.
Preparation requirements (if applicable) The container must be warmed to body temperature by holding it in the hands for a few minutes before administration to avoid an unpleasant sensation.
Age-group administration rules The preparation is suitable for both adults and children; dosage adjustments based on age are not required due to the localized effect.
Missed-dose rules If a dose is missed when following a regular schedule, apply the dose as soon as possible, or skip it if the next dose is almost due, without doubling the amount.
Special procedural conditions Prior verification of the tympanic membrane's integrity is a critical pre-administration procedural check documented in the administration guidelines.

Instruction classifications (high-level)

Classification Entity Description
Administration method type Topical (Localized).
Frequency pattern Multiple times daily (e.g., two to three times daily), or up to every one to two hours in an acute symptom context.
Basis of use Based on prescribing information for analogous otic analgesic/anaesthetic solutions.
Use-context constraints Duration of use is limited and should not exceed 7 to 10 days.

Resulting procedural structure

Step sequence:

  • Warming: The user must first warm the container by holding it in their hands.
  • Instillation: The prescribed drop count must be instilled into the external auditory canal.
  • Retention: The head must be kept tilted for approximately 5 minutes following the application.
  • Hygiene: Care must be taken to avoid contaminating the dropper tip during the instillation process.

Connection to the overall use protocol (2–4 sentences):

The use protocol for this otic solution begins with mandatory pre-use preparation (warming) and a physical pre-check for the ear's integrity. This sequence defines a standardized method of application based on a precise drop count and a structured frequency pattern intended to maintain use within the limited duration specified in use guidelines.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anaesthetic Ear Drop


Evidence for Symptomatic Pain Relief in Acute Otitis Media (AOM)

Research examining the combination of Phenazone and Tetracaine ear drops primarily consists of short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were studied for children, typically between 6 months and 10 years of age, who presented with ear pain relevant in trials assessing short-term or episodic symptom patterns associated with Acute Otitis Media (AOM).

In these studies, researchers examined outcomes related to physical discomfort, primarily measuring the change in ear pain scores at very short time intervals. Findings were mixed across studies; some trials described patterns suggesting differences in pain score changes compared to placebo, while others reported measurements that did not show a statistically distinct difference when compared only to the placebo solution. The research describes symptom patterns observed in the studies.

Research on Topical Anesthesia for Eardrum Procedures

The combination ear drop, specifically its anesthetic component Tetracaine, was studied for use in procedures requiring the numbing of the eardrum. Research often involves small-scale randomized trials where the ear drops are applied to the eardrum of adults prior to minor surgical procedures. These studies monitored patient-reported outcomes describing perceived discomfort and pain measured during the procedural stimulus.

Studies report how symptoms evolved in the observed populations related to the numbing effect achieved on the tympanic membrane. The data show patterns related to a brief duration of action, as observed in the procedural trials. Much of the data that describes the anaesthetic component is extrapolated from studies using Tetracaine alone or other similar local anesthetics in different formulations.

Areas of Uncertainty and Research Gaps

Evidence quality varies across studies, and a key limitation is the variability across studies, particularly regarding the exact measurements of pain reduction when compared to a vehicle placebo. This is because the soothing effect of the base liquid (like glycerin) alone makes it difficult to draw a conclusive statement on the specific patterns observed with the combination. Long-term effects are not fully established, as the focus of the clinical trials used in research exploring how symptoms change over time has been exclusively on short-term follow-up (e.g., up to eight days).

Key Studies & References

  1. Antipyrine and Benzocaine Otic Solution, USP Label (FDA-approved Drug Monograph)
  2. Analgesics for pain relief in acute otitis media (Cochrane Review Summary)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Anaesthetic Ear Drop (FAQ)


Q: How quickly should I expect Anaesthetic Ear Drop to start working?

Studies and official information indicate that the numbing component of the ear drop has a rapid onset of action. The maximum localized effect is often described as potentially occurring within seconds of the medicine being applied.


Q: How long does the numbing effect of the ear drop typically last?

The numbing component is described for short-term, symptomatic management. Information gathered from studies suggests that the localized numbing effect typically lasts for a relatively brief duration, often observed to be around 10 to 20 minutes.


Q: Why do some people need to warm the ear drop bottle before use?

The official instructions advise that the ear drop container must be warmed to body temperature before use. This is noted in instructions as a measure to help avoid causing temporary dizziness or an unpleasant sensation upon instillation.


Q: Can using these drops affect other medications I am taking?

Official labeling describes the potential for interaction with other local anaesthetics, certain CNS depressants (medicines that slow down the brain), and drugs that can affect metabolism. The regulatory information indicates that this is due to a potential for increased side effects.


Q: What are the most common reported side effects of this type of medication?

According to official product information, the most frequently reported adverse effects are temporary reactions occurring right at the application site. These typically include a transient stinging, burning, or mild irritation upon instillation.


Q: Is it possible to have an allergic reaction to Anaesthetic Ear Drop?

Regulatory information notes that the medicine is contraindicated if a patient has a known hypersensitivity or allergy to any of its ingredients. Rare systemic allergic reactions have been reported for the drug class, and the possibility of these reactions is noted in the regulatory information.


Q: Can I use this product multiple times a day?

The product's use is officially classified as 'multiple times daily' within a specific prescribed frequency range. This frequency is defined in the official dosing regimen for managing acute symptomatic contexts.


Q: Can Anaesthetic Ear Drop cause temporary hearing changes?

Regulatory reports for ingredients in this drug class list a potential for ear and labyrinth disorders. These potential symptoms include continuing ringing or buzzing in the ears (tinnitus) and, in serious cases, hearing loss.


Q: Is it normal to feel a stinging sensation right after putting in the drops?

Local reactions, such as a transient stinging or burning sensation, are frequently described in official documents as potentially occurring upon the initial application of the drops. This sensation is noted as a temporary event.


Q: Is there any official guidance on using Anaesthetic Ear Drop while pregnant or breastfeeding?

Official guidance indicates that the safety for using this product during pregnancy and lactation has generally not been established through adequate studies. Due to this lack of established data, the use of this product by pregnant or breastfeeding individuals is noted to require caution.


Q: Is the numbing agent absorbed into the bloodstream?

The active ingredients are formulated for localized topical use in the ear, and regulatory information notes that systemic exposure, or absorption into the bloodstream, is generally considered low. The medicine is primarily intended to act at the application site.


Q: Does the medicine only numb the outside of the ear?

The official route of administration is strictly the 'Auricular (Otic) Route' for topical use in the external auditory canal. This means the intended scope of action is localized to the external part of the ear canal and the outer surface of the eardrum.


Q: Can the drops cause temporary blurring of vision if they get near the eye?

It is officially advised to avoid contact with the eye when applying the drops. Regulatory information for the anaesthetic component lists temporary blurred vision as a possible adverse reaction if the medicine contacts the eyes.


Q: What color is the liquid in Anaesthetic Ear Drops usually?

The liquid solution is typically described in official product labeling as being clear. It may range in color from completely colorless to slightly yellow.


Q: Can I use this drop if I'm taking blood pressure medication?

Regulatory documents note caution regarding co-administration with other products that share similar effects on cardiac function. These include certain antiarrhythmics or beta-blockers, which are noted to share similar effects on cardiac function.


Q: Is it safe to drive after using Anaesthetic Ear Drop?

Official product information states that the product is not expected to affect an individual's ability to drive or use machinery. This is due to its intended localized topical action.


Q: Are there specific ingredients in the drop that can cause irritation?

The active anaesthetic component has been noted in studies to cause local irritation when applied to tissues. This is the underlying basis for the frequently reported local application site reactions like stinging and burning.


Q: Has any large-scale research studied the long-term effects of using these drops?

Official documents and research summaries state that the long-term effects of this product are not fully established. Clinical studies have primarily focused on short-term follow-up.

Advertisements

How should Anaesthetic Ear Drop be stored and disposed of?

Anaesthetic Ear Drop must be stored at controlled room temperature, typically between 20 C and 25 C. The solution must be kept from freezing and protected from light and excess heat. For protection, the medicine must remain in its original container and be kept tightly closed when not in use.

Regulatory labeling specifies that all medicine must be stored out of the sight and reach of children. The product's stability limits require it to be discarded six months after opening or by the printed expiration date, whichever occurs first. Unused or expired drops should be disposed of via a medicine take-back program. They must not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anaesthetic Ear Drop found in:

A-Z Index: